Xenon Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
Xenon Pharmaceuticals Inc (XENE) (Q3 2026) Earnings Call Highlights: $1. ...
Is Xenon Pharmaceuticals (XENE) Above Fair Value After Phase 2 Progress?
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals: Q3 Earnings Snapshot
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate
Xenon to Present at Upcoming Investor Conferences
Xenon to Report Q3 2026 Financial Results on November 9, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.